title: Multicenter evaluation of a new recombinant enzyme immunoassay for the combined detection of antibody to HIV-1 and HIV-2.
abstract: A newly developed recombinant antigen-based anti-HIV-1/HIV-2 enzyme immunoassay (Abbott Recombinant HIV-1/HIV-2 EIA) was evaluated against a second generation anti-HIV-1 EIA (Abbott Recombinant HIV-1 EIA). Five thousand and twenty-nine sera from European blood donors and 403 sera from central African blood donors were used in the evaluation, along with four panels and one cohort. The panels included 99 'problem' sera, 733 sera with antibodies to HIV-1 from asymptomatic people and from patients at different disease stages, 25 serial bleeds from five plasmapheresis donors seroconverting for antibodies to HIV-1, and 202 sera with antibodies to HIV-2 collected from healthy and diseased people of European or west African origin. In addition, 734 sera collected from a west African cohort were tested. Using Western blot as the reference standard, the specificity obtained by the recombinant anti-HIV-1 EIA (HIV-i EIA) was 99.90% [99.81-99.99%; 95% confidence limits (95% CL)] with European blood donor sera; 99.50% (98.78-100%) with Central Africa blood donor sera; 92.93% (87.78-98.08%) with 'problem' sera and 99.43% (98.87-100%) with sera from a west African cohort. Using the same samples, the recombinant anti-HIV-1/HIV-2 EIA (HIV-1/HIV-2 EIA) yielded a specificity of 99.84% (99.73-99.95%), 99.50% (98.78-100%), 95.96% (92.00-99.92%) and 98.58% (97.69-99.47%), respectively. All 776 Western blot-confirmed anti-HIV-1 sera were reactive in both EIAs, and the EIA-reactive samples from seroconverting plasma donors were always observed for both assays in the same serial bleed. For HIV-2, the HIV-1 EIA yielded an overall sensitivity of 75.83% (69.93-81.72%) compared with 99.53% (98.58-100%) for HIV-1/HIV-2 EIA. The addition of a recombinant env-protein of HIV-2 to the recombinant env and core proteins of HIV-1 on the solid phase of HIV-1 EIA improved the detection of anti-HIV-2 while preserving the assay's overall specificity and sensitivity for the detection of anti-HIV-1.
authors.affiliation: National Institute of Health, Lisbon, Portugal.
authors.forename: L
authors.initials: L
authors.lastname: Ayres
authors.forename: F
authors.initials: F
authors.lastname: Avillez
authors.forename: A
authors.initials: A
authors.lastname: Garcia-Benito
authors.forename: F
authors.initials: F
authors.lastname: Deinhardt
authors.forename: L
authors.initials: L
authors.lastname: Gürtler
authors.forename: F
authors.initials: F
authors.lastname: Denis
authors.forename: G
authors.initials: G
authors.lastname: Léonard
authors.forename: S
authors.initials: S
authors.lastname: Ranger
authors.forename: P
authors.initials: P
authors.lastname: Grob
authors.forename: H
authors.initials: H
authors.lastname: Joller-Jemelka
mesh_terms: D015492:AIDS Serodiagnosis / Q000379:methods*; D001782:Blood Donors; D015153:Blotting, Western; D005060:Europe; D005069:Evaluation Studies as Topic; D015483:HIV Antibodies / Q000032:analysis*; D006679:HIV Seropositivity / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology; D015528:HIV Seroprevalence; D015497:HIV-1 / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D006801:Humans; D007124:Immunoenzyme Techniques
chemical_list: D015483:HIV Antibodies